Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
sickle cell disease
Biotech
Pfizer's SCD drug fails ph. 3 study in latest blow to GBT legacy
Pfizer’s sickle cell disease drug flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics.
James Waldron
Aug 18, 2025 7:31am
Novo inks IMMvention deal to orchestrate attack on sickle cell
Jan 22, 2025 9:41am
Vertex and Orna team up to develop new blood disorder treatments
Jan 7, 2025 7:00am
Beam hits hemoglobin goal in first base editing clinical data
Nov 5, 2024 9:00am
Pfizer axes phase 3 sickle cell study, cites recruitment issues
Mar 26, 2024 5:31pm
ASH: Editas shares data for mid-stage sickle cell disease asset
Dec 11, 2023 2:33pm
